OCULAR MANIFESTATIONS OF SYSTEMIC DISEASE: Edited by John A. GonzalesDrug-induced maculopathyKhan, Mahmood J.a; Papakostas, Thanosa; Kovacs, Kylea; Gupta, Mrinali P.a,b Author Information aDepartment of Ophthalmology, Weill Cornell Medical College, New York, New York bRetina Associates of Orange County, Laguna Hills, California, USA Correspondence to Mrinali P. Gupta, MD, Retina Associates of Orange County, 23521 Paseo De Valencia #207, Laguna Hills, CA 92653, USA. Tel: +1 949 707 5125; e-mail: [email protected] Current Opinion in Ophthalmology: November 2020 - Volume 31 - Issue 6 - p 563-571 doi: 10.1097/ICU.0000000000000714 Buy Metrics Abstract Purpose of review The purpose of this article is to provide an overview of drug-induced maculopathies including their clinical presentations, diagnostic findings, and treatment options. With the increasing pace of development and arrival of drugs to the market, this review aims to inform retina specialists of relevant side effects that may be encountered in a clinical practice setting. Recent findings The major themes visited in this article focus on relevant findings of drugs that cause pigmentary and crystalline maculopathy, photoreceptor dysfunction, cystoid macular edema, central serous choroidopathy, uveitis, and vascular damage. Summary The current review reports updated findings and discusses the pathophysiologic mechanisms, presentations, and treatments of drug-induced maculopathies. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.